|
Title
|
|
|
|
Can positron emission tomography with []-fluorodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity?
|
|
|
Author
|
|
|
|
|
|
|
Abstract
|
|
|
|
| To assess the ability of restaging positron emission tomography (PET) scanning to predict clinical outcome after first-line treatment in patients with Hodgkin's disease, we included 60 patients with histologically proven HD, who underwent whole-body [18F]-fluorodeoxygenase ([18F]-FDG)-PET studies after first-line treatment and with a follow-up of at least 1 year. Persistence or absence of residual disease on PET was related to progression-free survival (PFS) using KaplanMeier survival analysis. After treatment, 55 patients showed a normal [18F]-FDG-PET scan; 50 of 55 remained in complete remission (CR), with a median follow-up of 955 d. Only five patients relapsed (median PFS, 296 d). During follow-up in all five patients, [18F]-FDG-PET was the first tool that became positive for relapse. Persistent abnormal [18F]-FDG uptake was seen in only five patients; all of them relapsed (median PFS, 296 d). In four of five patients, only PET predicted persistent disease. All relapses were proven histologically. Two-year actuarial PFS rate for negative patients was 91% compared with 0% for positive patients. We concluded that [18F]-FDG-PET has an important prognostic role in the post-treatment evaluation of HD patients. |
|
|
|
Language
|
|
|
|
English
|
|
|
Source (journal)
|
|
|
|
British journal of haematology. - Oxford
|
|
|
Publication
|
|
|
|
Oxford
:
2001
|
|
|
ISSN
|
|
|
|
0007-1048
|
|
|
DOI
|
|
|
|
10.1046/J.1365-2141.2001.03169.X
|
|
|
Volume/pages
|
|
|
|
115
:2
(2001)
, p. 272-278
|
|
|
ISI
|
|
|
|
000172403300007
|
|
|
Full text (Publisher's DOI)
|
|
|
|
|
|
|
Full text (publisher's version - intranet only)
|
|
|
|
|
|